Skip to main content
Figure 2 | BMC Biotechnology

Figure 2

From: Addition of a sequence from α2-antiplasmin transforms human serum albumin into a blood clot component that speeds clot lysis

Figure 2

Factor XIIIa-mediated incorporation of BPA or dansyl cadaverine into α 2 AP and fusion proteins. (A) Relevant portions of streptavidin blots containing the reaction products of the proteins identified below the panels with 10 mM BPA in the presence of thrombin, FXIII, calcium, and 7.14 μM test proteins, for the times in minutes shown above the lanes, using reaction conditions described in "Methods". Lanes labelled "No FXIII" and "No Ca++" correspond to reactions identical to those shown for α2AP at 120 minutes, with the omission of the listed components. (B) Portions of 8% SDS-acrylamide gels visualized by ultraviolet transillumination following fXIIIa-mediated transglutamination of 0.5 mM dansyl cadaverine to the proteins listed the right of the panels. (C) Same as panel A, except that all reactions contained α2AP at 1.7 μM, reacted with BPA, thrombin and FXIII in the presence of the concentrations of either α2AP(13-42) synthetic peptide (13-42 Pep), α2AP(13-42)-HSA (13-42 FP for fusion protein) shown above the lanes. The positions of α2AP and α2AP(13-42)-HSA are highlighted at right.

Back to article page